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Abstract
Introduction: Germline TP53 mutations cause an increased risk to early-onset breast cancer in Li-Fraumeni
syndrome (LFS) families and the majority of carriers identified through breast cancer cohorts have LFS or Li-
Fraumeni-like (LFL) features. However, in Asia and in many low resource settings, it is challenging to obtain
accurate family history and we, therefore, sought to determine whether the presence of early-onset breast cancer
is an appropriate selection criteria for germline TP53 testing.
Methods: A total of 100 patients with early-onset breast cancer (≤ 35 years) treated at University Malaya Medical
Centre between 2003 and 2009, were analyzed for germline mutations in BRCA1, BRCA2 and TP53 by full DNA
sequencing. Of the mutations identified, we examined their likely pathogenicity on the basis of prevalence in a
case-control cohort, co-segregation analyses and loss of heterozygosity (LOH) in tumor tissues.
Results: We identified 11 BRCA1 (11%) and 6 BRCA2 (6%) germline carriers among early-onset breast cancer
patients. Of the 83 BRCA-negative patients, we identified four exonic variants and three intronic variants in TP53. Of
these, two exonic variants are clinically relevant (E346X and p. G334_R335dup6) and two novel missense mutations
(A138V and E285K) are likely to be clinically relevant, on the basis of co-segregation and loss of heterozygosity
(LOH). Notably, E285K was found in two unrelated individuals and haplotype analyses suggest a founder effect.
Two of the three intronic variants are likely benign based on their prevalence in a control population. Clinically
relevant TP53 germline mutations were identified in three of the four patients (75%) with a family history of at least
two LFS-linked cancers (breast, bone or soft tissue sarcoma, brain tumors or adrenocortical cancer); 1 of the 17
patients (6%) with a family history of breast cancer only, and 1 of the 62 patients (< 2%) with no family history of
breast or LFS-linked cancers.
Conclusions: Our study reports germline BRCA1, BRCA2 and TP53 mutations are found in early-onset breast cancer
patients at 11%, 6% and 5% respectively, suggesting that TP53 mutation screening should be considered for these
patients. However, we find that even in low resource Asian settings where family history is poorly reported,
germline TP53 mutations are found predominantly among breast cancer patients with a family history of LFS-linked
cancers.
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Introduction
To date, germline mutations in at least 10 genes linked to
DNA repair have been shown to be associated with an
inherited risk for breast cancer [1]. This includes TP53, a
tumor suppressor gene that plays a pivotal role in the
cell’s response to DNA damage by inducing pathways
involved in apoptosis, cell cycle arrest and the DNA
repair mechanism in order to maintain the cell’s genomic
integrity [2].
Although rare, germline mutations in TP53 are asso-
ciated with a significantly increased risk of female breast
cancer, bone or soft tissue sarcomas, brain tumors and
adrenocortical carcinomas (ACC) [3-7]. To date, the
majority of studies have examined the prevalence of
TP53 germline mutations among families identified
through the genetics clinics and these studies have
shown that the majority of families with germline TP53
mutations fulfill either the original Li-Fraumeni syn-
drome (LFS) criteria, Li-Fraumeni-like (LFL) criteria or
the Chompret criteria and are present with a family his-
tory of at least one of the four LFS-linked cancers (breast,
bone or soft tissue sarcomas, brain tumors and ACC)
[1,5,8,9]. More recently, population-based studies have
found TP53 germline mutations among women with
early-onset breast cancer aged 40 years and below
[10,11].
However, the reliance on family history and recruitment
through the genetics clinics poses significant challenges in
many Asian countries, particularly low and middle income
countries such as Malaysia. Clinical genetics services are
relatively new and underdeveloped and, moreover, our
data and data from Asian Americans have shown that risk
assessment models for BRCA1 and BRCA2, which were
largely built on families with multiple cancers, underesti-
mate the number of BRCA carriers in Asians compared to
Caucasians [12,13]. We have previously found that family
history is poorly reported in Asian families in Malaysia, in
part due to the stigma associated with cancer in Asian
families, significant geographical dispersal of families and
the lack of robust cancer registries [12,14]. There is cur-
rently no data in any Asian cohort to determine whether
this underestimation of number of carrier families also
applies to other genes.
In order to determine the significance of TP53 germline
mutations to breast cancer risk in our multi-ethnic cohort,
we sought to determine the prevalence of TP53 germline
mutations in a hospital-based cohort of Asian breast can-
cer patients diagnosed before age 35 years. Of the muta-
tions identified, we examined their likely pathogenicity on
the basis of prevalence in a case-control cohort, co-segre-




A total of 1,060 breast cancer patients, who were treated
at University Malaya Medical Centre, Kuala Lumpur
between January 2003 and December 2009, were
recruited into the Malaysian Breast Cancer Genetics
Study (MyBrCa). All patients gave informed consent and
the study was approved by the University Malaya Medi-
cal Centre ethics committee.
BRCA1 and BRCA2 sequencing and large chromoso-
mal deletion analysis was conducted in all patients diag-
nosed with invasive breast cancer aged below 35 years
and those with a family history of breast and/or ovarian
cancer [12,15]. Of the BRCA-negative patients, we
screened for germline TP53 mutations in all 83 women
who developed invasive breast cancer before 35 years of
age, regardless of family history.
Mutation detection
Genomic DNA isolation and DNA sequencing was con-
ducted as previously described [15]. Full DNA sequen-
cing was carried out in both directions on the entire
TP53 coding region and intron-exon boundaries, and
annotated using HGVS nomenclature with the GenBank
reference sequence NC_000017.9.
Case-control studies
Genotyping analyses of the seven mutations identified in
this study were conducted using the Sequenom Mas-
sARRAY platform (San Diego, CA, USA) on 880 women
(181 Malays, 530 Chinese, 169 Indians) with invasive
breast cancer and on 270 female controls (90 Malays, 90
Chinese, 90 Indians). All mutations identified were con-
firmed by DNA sequencing.
Haplotyping analyses
Four TP53 microsatellite markers were used as pre-
viously described: p53CA, an intragenic dinucleotide
marker; VNTR, a marker with a pentanucleotide repeat
in intron 1 [16] and two markers flanking the TP53
gene, D17S786 and D17S796 [17].
Loss of heterozygosity (LOH) analyses
Where available, 15 to 20 μM of formalin fixed paraffin-
embedded (FFPE) specimens were retrieved for DNA
analyses. Each sample had approximately 40 to 80%
tumor cells and genomic DNA was isolated using the
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol. LOH analyses
were conducted by DNA sequencing and genotyped
using the Sequenom MassARRAY platform (San Diego,
CA, USA).
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Results
In our ongoing study of breast cancer predisposition genes
in a hospital-based cohort of breast cancer patients, we
have analyzed BRCA1 and BRCA2 in all patients younger
than 35 years diagnosed with invasive breast cancer.
Between January 2003 and December 2009, 281 patients
were diagnosed with invasive breast cancer before age 35
years at the University Malaya Medical Centre, Kuala
Lumpur and 100 patients were recruited into the MyBrCa
study. Of these, 11 (11%) and 6 (6%) were found to have
deleterious mutations in BRCA1 and BRCA2 respectively.
We have analyzed germline TP53 mutations in the
remaining 83 individuals who tested negative for both
BRCA1 and BRCA2 mutations (Table 1). Of these patients,
4 (4.8%) had a family history of at least one case of the
other LFS-linked cancers (bone or soft tissue sarcoma,
brain tumors or ACC), 17 (20.5%) had a family history of
breast cancer only, and the remaining 62 had no family
history of any of the LFS-linked cancers. Mutation ana-
lyses have revealed four unique exonic germline muta-
tions; of which one (E285K) was found in two unrelated
individuals, and three unique intronic germline mutations;
of which one (c.74 + 14 T > C) was found in two unrelated
individuals (Table 2).
Notably of the five exonic TP53 mutation carriers,
three had a family history of LFS-linked cancers, one
had two cases of early-onset breast cancer in the family
and one had no family history of cancer.
Mutation c.1036 G > T (p. E346X)
This mutation was found in a Malay individual, BRC 901,
with no reported family history of any cancer (Figure 1a).
She was diagnosed with breast cancer at age 25, with
recurrence in the same breast at age 26. At age 29, she
developed Stage 4 contralateral breast cancer with
metastasis to the bones, liver and lungs. This mutation,
E346X, was found to be located within the tetramerization
domain of TP53 and has previously been reported as a
somatic mutation occurring in one tumor only (IARC
TP53 database) [18].
Mutation c.1001_1006dup6 (p. G334_R335dup)
This mutation was found in a Malay individual, BRC
564, whose family showed classic LFS features (Figure
1b). She presented with breast cancer at age 26 and con-
tralateral breast cancer at age 27, and has one child
diagnosed with embryonal rhabdomyosarcoma (ERMS)
at eight months and another child with ACC at six
months. The patient’s mother was diagnosed with breast
cancer at age 38 and her younger sister had osteosar-
coma at age 26. Upon further analysis, it was found that
this family was previously tested in the same hospital
for TP53 mutations due to the presence of the child-
hood cancers. Further analyses have revealed two unaf-
fected children and an unaffected brother as TP53
carriers, in addition to her two affected children and her
younger sister with osteosarcoma [19].
This mutation, which is located within the TP53 tetra-
merization domain, involves a duplication of a 6 bp
GGCGTG sequence, which results in an in-frame inser-
tion of two amino acids (Arg and Gly), and is predicted
to be likely deleterious.
Mutation c.413 C > T (p. A138V)
This mutation was found in a Chinese individual, BRC 349,
with LFL features (Figure 1c). The proband was diagnosed
with breast cancer at age 32, with two sisters (BRC 349A
and BRC 349B) affected by breast cancer at 33 and 34
years of age. Notably, one of her sisters, BRC 349A, was
subsequently diagnosed with uterine leiomyosarcoma and
stomach adenocarcinoma at 43 and 46 years of age, respec-
tively, and was shown to have the same germline TP53
mutation. Her older brother was diagnosed with colorectal
cancer at age 33 years, a younger brother was described by
the family as having a tumor in the ‘gluteal region’, her
father was affected with liver cancer at an unknown age
and a niece was affected with a brain tumor at age 10.
The A138V mutation was found to be located within
the DNA binding domain of TP53. This mutation has
previously been reported as a somatic mutation in 51
tumors and, by in silico analysis with Align-GVGD, is
predicted to be likely deleterious (IARC TP53 database)
[18]. Notably, analysis of the DNA from FFPE breast
cancer samples from BRC349 showed loss of the wild
type TP53 allele (Figure 2a).
Mutation TP53 c.853 G > A (p. E285K)
This mutation was found in two unrelated Chinese indi-
viduals (Figure 1d, e). The first patient, BRC832, was
Table 1 Characteristics of families recruited into the TP53






Family history (1° and 2° relatives)
1 case of breast cancer 13 16
2 cases of breast cancer 3 4
≥ 3 cases of breast cancer 1 1
No family history of breast and/or ovarian cancer 62 75
≥ 1 case of LFS-linked cancers 4 5
Table 1 shows the characteristics of 83 BRCA-negative early-onset breast
cancer patients analyzed for germline TP53 mutations according to their
ethnicity, personal and/or family history of breast cancer in first- and second-
degree relatives and the presence of LFS-linked cancers (breast cancer, bone
and soft tissue sarcoma, brain tumors, adrenocortical carcinoma (ACC)) in the
families.
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first diagnosed with breast cancer at 31 years, with a
recurrence at 33 years. Her mother was diagnosed with
breast cancer at age 30 and her brother with a brain
tumor at age 20 years.
The second patient, BRC873, developed breast cancer at
age 29 and contralateral breast cancer at age 31. The pro-
band’s younger sister, BRC 873A, developed bilateral
breast cancer at the ages of 27 and 32, and was shown to
have the same germline TP53 mutation. Other family his-
tory included her paternal grandmother being affected
with breast cancer at 33 years of age and her father having
bone cancer at 52 years.
The E285K mutation is located within the DNA binding
domain of TP53. This mutation has previously been
reported as a somatic mutation in 169 tumors and by in
silico analysis with Align-GVGD, is predicted to likely be
deleterious (IARC TP53 database) [18]. Haplotype analysis
showed that these two families shared the same haplotype
across the four microsatellite markers tested (data not
shown). Analysis of the DNA from FFPE breast cancer
samples from BRC873 showed that there was no loss of
the wild type TP53 allele (Figure 2b)
Intronic sequence variants
We have identified three intervening sequence mutations:
c.74+14 T > C in two unrelated individuals, and c.97-28
T > A and c.672+18 G > C in one individual each. The
mutation c. 672+18G > C was reported as a somatic muta-
tion occurring in three tumors (IARC TP53 database) [18]
whereas the remaining two mutations have not previously
been reported.
Case-control studies
None of the four exonic mutations identified in this study
or the intervening sequence variant c.97-28 T > A, were
found in any of the 880 unselected invasive breast cancer
cases and 270 controls tested. Notably, c.74+14 T > C was
found in 12/880 (1.4%) and 2/270 (0.74%) controls, and
c.672+18 G > C was found in 14/880 (1.6%) breast cancer
cases and 2/270 (0.74%) controls; suggesting that both var-
iants are likely to be benign polymorphisms.
Histopathological analysis
Breast cancers arising in germline TP53 mutation carriers
were previously reported to be more likely to have amplifi-
cation of HER2 as compared to non-TP53 carriers [20,21].
Of the seven breast cancer patients (five index and
two family members) with germline exonic mutations in
TP53 available for review, six have strong amplification
of the HER-2 receptor (Table 3).
Discussion
Our study has shown that 5/83 (6%) of BRCA-negative
Asian breast cancer patients diagnosed before age 35 years
have germline exonic mutations in TP53 and that the
average age of onset of breast cancer was 31 years. This is
consistent with reports in other studies, where 0.8 to 5%
frequency was reported among breast cancer patients
diagnosed ≤ 40 years: in an clinic-based cohort of patients
≤ 40 years, 1/126 (0.8%) had a TP53 missense mutation
[22]; in a Singaporean clinic-based cohort of breast cancer
patients ≤ 35 years, 1/30 (3.3%) patients had a deleterious
TP53 mutation [23]: in an Australian population-based
cohort of two subgroups of early-onset breast cancer
patients (≤ 30 years and 31 to 39 years), 5/94 (5.3%) had
germline TP53 mutations [10].
Notably, in our study, three of the four families with
LFS-linked cancers had TP53 germline mutations. Other
genetics clinic-based testing showed that classical LFS
criteria, LFL criteria or the Chompret criteria are useful













1 10 c. 1036G > T p. E346X Nonsense Yes1 1 Deleterious Malay
2 10 c. 1001_1006dup6 p. G334_R335dup Duplication Yes2 1 Likely
deleterious
Malay
3 5 c. 413C > T p. A138V Missense Yes1 1 Likely
deleterious
Chinese





c. 74+14T > C - IVS Novel 2 Likely benign Chinese
6 Intron
3
c. 97-28T > A - IVS Novel 1 Unknown Chinese
7 Intron
6
c. 672+18G > C - IVS Yes1 1 Likely benign Malay
Mutation classification was made based on known databases or published studies.
1Reported in IARC TP53 database [18]. 2Ariffin et al., 2008 [19]. IVS, intervening sequence
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Figure 1 Pedigrees of families with germline exonic mutations in TP53. Pedigrees of the following families: (a) Family BRC 901 with
mutation TP53 p. E346X (b) Family BRC 564 with mutation TP53 p. G334_R335dup. (c) Family BRC 349 with mutation TP53 p. A138V (d) Family
BRC 832 with mutation TP53 p. E285K (e) Family BRC 873 with mutation TP53 p. E285K. Index patients are indicated with an arrow. Individuals
with cancer are indicated with filled symbol quadrants. Deceased individuals are indicated with a slash. Carriers with germline TP53 mutations
are indicated with a “+” and non-carriers with a “-”. ACC, adrenocortical carcinoma; Br ca, breast cancer; Bilat Br ca, bilateral breast cancer, CRC,
colorectal cancer; ERMS, embryonal rhabdomyosarcoma; Uterine LMS, uterine leiomyosarcoma.
Lee et al. Breast Cancer Research 2012, 14:R66
http://breast-cancer-research.com/content/14/2/R66
Page 5 of 8
                      BRC349 (Control)                                                    BRC349 (Tumour)    
 












                   










Allele G                                    Allele A                Allele G                                    Allele A     
 
Figure 2 Mass spectra of germline TP53 mutations p. A138V (c. 413C > T) and p. E285K (c. 853G > A) for LOH analyses. (a) Loss of the
wildtype C allele observed for sample extracted from FFPE breast cancer sample from BRC349 where 80% was tumor tissue (b) No LOH was
observed for sample extracted from FFPE breast cancer sample from BRC873 where > 40% was tumor tissue. Left panel, control blood samples;
Right panel, tumor samples; LOH, loss of heterozygosity.
Table 3 Histopathological characteristics of breast cancers in individuals with TP53 germline mutations
Mutation Patient no. Age at diagnosis Diagnosis Histology Grade ER status PR status HER-2 status
p. E346X BRC 901 25 Breast ca, L IDC with DCIS NA - + +
26 Breast ca, L IDC 3 + + 3+
29 Breast ca, R IDC NA NA NA NA
p. G334_R335dup BRC 564 26 Breast ca, R IDC NA NA NA NA
27 Breast ca, L IDC 3 - + 3+
p. A138V BRC 349 33 Breast ca, R IDC 3 - - 3+
BRC 349A 33 Breast ca, L IDC 2 - - -
p. E285K BRC 832 31 Breast ca, R IDC 2 - - 3+
BRC 873 29 Breast ca, R IDC with DCIS 3 - - 3+
31 Breast ca, L NA NA NA NA NA
BRC 873A 27 Breast ca, L NA NA NA NA NA
31 Breast ca, R Mucinous 2 + + 3+
Breast ca, breast cancer; DCIS, ductal carcinoma in situ; ER, estrogen receptor; IDC, invasive ductal carcinoma; HER-2, human epidermal growth factor receptor 2;
L, left; NA, not available; PR, progesterone receptor; R, right
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in selecting families for TP53 testing. In a study of 180
Dutch families, TP53 mutations were found in 22/24
patients who fulfilled the Chrompret criteria and 18/24
patients who fulfilled either classic LFS or LFL criteria
[9]. In a clinic-based study of a cohort of 525 indivi-
duals, 71/75 TP53 mutation carriers were shown to
meet either classic LFS or Chompret criteria [8].
The majority of studies have been from clinical genet-
ics units and recent breast cancer cohort studies suggest
that not all germline TP53 mutation carriers meet either
classic LFS or LFL criteria. Indeed, in our study, two out
of five TP53 mutation carriers did not meet classic LFS
or LFL criteria. Similarly, in an Australian study of 94
breast cancer patients, only two out of five carriers met
either classic LFS or LFL criteria [10] and in a UK-
based study of 100 breast cancer patients, two out of
four carriers met these criteria [11].
Our study has identified four exonic mutations
(A138V, E285K, E346X and p. G334_R335dup), three of
which have not previously been identified as germline
mutations. Through co-segregation and LOH studies,
we show that A138V and E285K are likely to be patho-
genic. In addition, we show that E285K is recurrent in
two unrelated Chinese families. Other recurrent muta-
tions have previously been reported, including the TP53
R337H mutation in southern Brazil [16] and the M133T
mutation found in two unrelated African-American
families [24], but to the best of our knowledge, this is
the first report of a recurrent TP53 mutation in an
Asian population.
In addition, our study has also identified three intronic
variants (c. 74+14 T > C, c. 97-28 T > A and c. 672+18
G > C), of which c. 74+14 T > C and c. 672+18 G > C
are benign as we show that they are also found in non-
cancer control individuals.
Notably, in our cohort of early-onset breast cancer
patients, 11%, 6% and 5% had germline mutations in
BRCA1, BRCA2 and TP53 respectively. Given the com-
parable frequency of BRCA1, BRCA2 and TP53 muta-
tions among patients diagnosed at ≤ 35 years and the
high penetrance of TP53 mutations, we suggest that all
patients who develop breast cancer at ≤ 35 years of age
should be offered genetic counseling and a family his-
tory of LFS-linked cancers should be carefully obtained.
Our findings are consistent with the recommendation
by the National Comprehensive Cancer Network
(NCNN) that all breast cancer patients who are diag-
nosed before the age of 30 and are BRCA-negative
should be offered genetic counseling and testing for
TP53 [25].
In addition, our data show that HER2 amplification
may be a useful marker in identifying TP53 germline
carriers, as six of the seven breast tumors (86%) in TP53
germline mutation carriers had amplification of ERBB2
(HER2). Previous reports found that 20/29 (69%) and
10/12 (83%) of breast tumors from germline TP53 car-
riers had HER2 amplification or over-expression [20,21]
and having a HER-amplified tumor increased the odds
of having TP53 germline mutation by nearly seven-fold
[21]. These data are consistent with the observation that
somatic mutations in TP53 are found in the majority of
HER2-amplified tumors, but the mechanism of interde-
pendence between TP53 and HER2 require further work
[20,21].
Conclusions
In conclusion, we show that TP53 germline mutations
occur at a comparable frequency with BRCA1 and
BRCA2 germline mutations among Asian early-onset
breast cancer patients, and occur predominantly, but
not exclusively, among families which have a family his-
tory of LFS-linked cancers.
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